Literature DB >> 23007895

Prevalence of venous thromboembolism in patients with secondary polycythemia.

Omar Nadeem1, Jiang Gui, Deborah L Ornstein.   

Abstract

To investigate an association between secondary polycythemia and venous thromboembolism (VTE) risk, we performed a case-control study to compare the prevalence of VTE in participants with secondary polycythemia due to chronic obstructive pulmonary disease (COPD; N = 86) to that in age- and sex-matched controls with COPD without secondary polycythemia (N = 86). Although there was a significant difference in mean hematocrit between cases and controls (53.5% vs 43.6%, respectively; P < .005), we identified no difference in the number of total or idiopathic VTE events in the 2 groups. Patients with VTE, however, had a significantly higher body mass index than patients without VTE. Our findings suggest that secondary polycythemia alone may not be a significant risk factor for VTE but that VTE risk in this population may be related to known risk factors such as obesity. The role of phlebotomy for VTE risk reduction secondary polycythemia is therefore questionable.

Entities:  

Keywords:  obesity; phlebotomy; polycythemia; venous thromboembolism

Mesh:

Year:  2012        PMID: 23007895      PMCID: PMC3831025          DOI: 10.1177/1076029612460425

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  17 in total

1.  Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.

Authors:  A Falanga; M Marchetti; V Evangelista; A Vignoli; M Licini; M Balicco; S Manarini; G Finazzi; C Cerletti; T Barbui
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

2.  Prevention of thrombosis in polycythemia vera and essential thrombocythemia.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro
Journal:  Haematologica       Date:  2008-03       Impact factor: 9.941

3.  Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment1+2 levels in patients with polycythemia vera: mechanism of activation of blood coagulation.

Authors:  A Kornberg; N Rahimi-Levene; R Yona; A Mor; E A Rachmilewitz
Journal:  Am J Hematol       Date:  1997-09       Impact factor: 10.047

4.  Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro; Tiziano Barbui; Valerio De Stefano; Guido Finazzi; Rosamaria Marfisi; Gianni Tognoni; Roberto Marchioli
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

5.  The haematocrit and platelet target in polycythemia vera.

Authors:  Marcello Di Nisio; Tiziano Barbui; Leonardo Di Gennaro; Giovanna Borrelli; Guido Finazzi; Raffaele Landolfi; Giuseppe Leone; Rosamaria Marfisi; Ettore Porreca; Marco Ruggeri; Anne W S Rutjes; Gianni Tognoni; Alessandro M Vannucchi; Roberto Marchioli
Journal:  Br J Haematol       Date:  2006-12-08       Impact factor: 6.998

Review 6.  Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.

Authors:  A Wehmeier; T Südhoff; F Meierkord
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

7.  Reduced in vitro clot lysis and release of more active platelet PAI-1 in polycythemia vera and essential thrombocythemia.

Authors:  E Pósán; G Ujj; A Kiss; B Telek; K Rák; M Udvardy
Journal:  Thromb Res       Date:  1998-04-15       Impact factor: 3.944

8.  Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia.

Authors: 
Journal:  Ann Intern Med       Date:  1995-11-01       Impact factor: 25.391

9.  Efficacy and safety of low-dose aspirin in polycythemia vera.

Authors:  Raffaele Landolfi; Roberto Marchioli; Jack Kutti; Heinz Gisslinger; Gianni Tognoni; Carlo Patrono; Tiziano Barbui
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

10.  Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.

Authors:  P D Berk; J D Goldberg; P B Donovan; S M Fruchtman; N I Berlin; L R Wasserman
Journal:  Semin Hematol       Date:  1986-04       Impact factor: 3.851

View more
  15 in total

1.  Relationship between polycythemia and in-hospital mortality in chronic obstructive pulmonary disease patients with low-risk pulmonary embolism.

Authors:  Lu Guo; Aamer Rasheed Chughtai; Hongli Jiang; Lingyun Gao; Yan Yang; Yang Yang; Yuejian Liu; Zhenliang Xie; Weimin Li
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

2.  Mesenteric vein thrombosis caused by secondary polycythaemia from AndroGel.

Authors:  Heather Katz; Eugene Popov; Natasha Bray; Barry Berman
Journal:  BMJ Case Rep       Date:  2014-10-21

3.  Polycythemia-Related Proliferative Ischemic Retinopathy Managed with Smoking Cessation: A Case Report.

Authors:  Shao-Yu Sung; Yo-Chen Chang; Horng-Jiun Wu; Hung-Chi Lai
Journal:  Int J Environ Res Public Health       Date:  2022-06-30       Impact factor: 4.614

4.  Global REACH 2018: dysfunctional extracellular microvesicles in Andean highlander males with excessive erythrocytosis.

Authors:  L Madden Brewster; Anthony R Bain; Vinicius P Garcia; Hannah K Fandl; Rachel Stone; Noah M DeSouza; Jared J Greiner; Michael M Tymko; Gustavo A Vizcardo-Galindo; Romulo J Figueroa-Mujica; Francisco C Villafuerte; Philip N Ainslie; Christopher A DeSouza
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-03-12       Impact factor: 4.733

5.  Secondary polycythemia and the risk of venous thromboembolism.

Authors:  Vijaya Raj Bhatt
Journal:  J Clin Med Res       Date:  2014-07-28

6.  Comparison and evaluation of two different methods to establish the cigarette smoke exposure mouse model of COPD.

Authors:  Jiaze Shu; Defu Li; Haiping Ouyang; Junyi Huang; Zhen Long; Zhihao Liang; Yuqin Chen; Yiguan Chen; Qiuyu Zheng; Meidan Kuang; Haiyang Tang; Jian Wang; Wenju Lu
Journal:  Sci Rep       Date:  2017-11-13       Impact factor: 4.379

Review 7.  A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

Authors:  Mary F F McMullin; Adam J Mead; Sahra Ali; Catherine Cargo; Frederick Chen; Joanne Ewing; Mamta Garg; Anna Godfrey; Steven Knapper; Donal P McLornan; Jyoti Nangalia; Mallika Sekhar; Frances Wadelin; Claire N Harrison
Journal:  Br J Haematol       Date:  2018-11-13       Impact factor: 6.998

8.  Phenotypical differences and thrombosis rates in secondary erythrocytosis versus polycythemia vera.

Authors:  Eliane Nguyen; Michaël Harnois; Lambert Busque; Shireen Sirhan; Sarit Assouline; Ines Chamaki; Harold Olney; Luigina Mollica; Natasha Szuber
Journal:  Blood Cancer J       Date:  2021-04-15       Impact factor: 11.037

9.  Secondary polycythemia in chronic obstructive pulmonary disease: prevalence and risk factors.

Authors:  Michael H Cho; Brian D Hobbs; Jingzhou Zhang; Dawn L DeMeo; Edwin K Silverman; Barry J Make; R Chad Wade; J Michael Wells
Journal:  BMC Pulm Med       Date:  2021-07-14       Impact factor: 3.320

10.  A case report of late-onset symptoms of erythrocytosis in univentricular dextrocardia.

Authors:  Lishui Shen; Jin Zhao; Tingting Yuan; Mengjie Li; Yun Cheng
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.